Muddled Picture for DMD Drug

January 16, 2014 5:27 PM

17 0

The exon-skipping agent eteplirsen appears to have greatly slowed the decline in walking ability in six boys with Duchenne muscular dystrophy (DMD) treated for more than 2 years, the drug's manufacturer announced Wednesday.

But a problem remains -- the FDA has already told the firm that this and the study's other major outcome measure (a biomarker measurement) may not be suitable.

Read more

To category page